CY1119522T1 - (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη - Google Patents

(r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη

Info

Publication number
CY1119522T1
CY1119522T1 CY20171101122T CY171101122T CY1119522T1 CY 1119522 T1 CY1119522 T1 CY 1119522T1 CY 20171101122 T CY20171101122 T CY 20171101122T CY 171101122 T CY171101122 T CY 171101122T CY 1119522 T1 CY1119522 T1 CY 1119522T1
Authority
CY
Cyprus
Prior art keywords
acceptable salts
pilindol
pharmaceuticalally
medicine
pyrindol
Prior art date
Application number
CY20171101122T
Other languages
English (en)
Inventor
Augusto Eugénio PARDAL FILIPE
Pedro Filipe EUFRÁSIO PEDROSO
Susana Marques ALMEIDA PECORELLI
Carlos Alberto Eufrásio CASIMIRO CAIXADO
Ana Sofia da Conceição LOPES
João Carlos Ramos DAMIL
Original Assignee
Tecnimede-Sociedade Tecnico-Medicinal, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tecnimede-Sociedade Tecnico-Medicinal, S.A. filed Critical Tecnimede-Sociedade Tecnico-Medicinal, S.A.
Publication of CY1119522T1 publication Critical patent/CY1119522T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Abstract

(R)-πιρλινδόλη ή τα φαρμακευτικώς αποδεκτά άλατα αυτής, καθώς και φαρμακευτικές συνθέσεις που περιλαμβάνουν αυτήν(ά) για χρήση στη θεραπευτική αγωγή και πρόληψη πόνου.
CY20171101122T 2014-05-09 2017-10-30 (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη CY1119522T1 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/PT2014/000028 WO2015171004A1 (en) 2014-05-09 2014-05-09 (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine

Publications (1)

Publication Number Publication Date
CY1119522T1 true CY1119522T1 (el) 2018-03-07

Family

ID=50819930

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171101122T CY1119522T1 (el) 2014-05-09 2017-10-30 (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη

Country Status (28)

Country Link
US (2) US20170145015A1 (el)
EP (1) EP3054950B1 (el)
JP (1) JP2017514884A (el)
KR (1) KR102232198B1 (el)
CN (1) CN106413714A (el)
AU (1) AU2014393489B2 (el)
CA (1) CA2948596C (el)
CY (1) CY1119522T1 (el)
DK (1) DK3054950T3 (el)
EC (1) ECSP16086232A (el)
ES (1) ES2649491T3 (el)
HR (1) HRP20171650T1 (el)
HU (1) HUE035030T2 (el)
IL (1) IL248854B (el)
LT (1) LT3054950T (el)
MA (1) MA39448B1 (el)
MX (1) MX368735B (el)
NO (1) NO3054950T3 (el)
NZ (1) NZ726131A (el)
PH (1) PH12016502236A1 (el)
PL (1) PL3054950T3 (el)
PT (1) PT3054950T (el)
RS (1) RS56590B1 (el)
RU (1) RU2695607C2 (el)
SI (1) SI3054950T1 (el)
TN (1) TN2016000497A1 (el)
UA (1) UA116499C2 (el)
WO (1) WO2015171004A1 (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6400121B2 (ja) * 2014-05-09 2018-10-03 テクニメデ ソシエダーデ テクニコ−メディシナル エス．アー． 医療用のピルリンドールエナンチオマーの薬学的に許容可能な塩
MX368735B (es) 2014-05-09 2019-10-14 Tecnimede Sociedade Tecnico Medicinal S (r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina.
KR102421013B1 (ko) * 2016-05-19 2022-07-14 에스케이바이오팜 주식회사 삼차신경통을 예방 또는 치료하기 위한 카바메이트 화합물의 용도
US20210386365A1 (en) * 2018-06-13 2021-12-16 Children`S Medical Center Corporation Biomarkers of neuropathic pain

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05003550A (es) * 2002-10-03 2006-01-24 Cypress Bioscience Inc Incremento de dosificacion y dosis diaria dividida de anti-depresivos para tratar padecimientos neurologicos.
NZ541282A (en) * 2002-12-24 2009-02-28 Bellus Health International Ltd Therapeutic formulations for the treatment of beta-amyloid related diseases
JP2007505831A (ja) * 2003-09-15 2007-03-15 ベクトゥラ・リミテッド 肺吸入による、早漏を治療するための医薬品組成物
EP1688161A1 (en) * 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
PT3057589T (pt) * 2014-05-09 2017-11-29 Tecnimede-Sociedade Tecnico-Medicinal S A (s)-pirlindol ou seus sais farmaceuticamente aceitáveis para uso em medicina
JP6400121B2 (ja) * 2014-05-09 2018-10-03 テクニメデ ソシエダーデ テクニコ−メディシナル エス．アー． 医療用のピルリンドールエナンチオマーの薬学的に許容可能な塩
MX368735B (es) 2014-05-09 2019-10-14 Tecnimede Sociedade Tecnico Medicinal S (r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina.

Also Published As

Publication number Publication date
IL248854B (en) 2020-05-31
IL248854A0 (en) 2017-01-31
UA116499C2 (uk) 2018-03-26
ECSP16086232A (es) 2017-02-24
RU2016148182A (ru) 2018-06-13
HUE035030T2 (en) 2018-05-02
EP3054950B1 (en) 2017-08-02
CN106413714A (zh) 2017-02-15
MA39448B1 (fr) 2019-12-31
MX368735B (es) 2019-10-14
CA2948596C (en) 2021-06-08
PL3054950T3 (pl) 2018-02-28
DK3054950T3 (en) 2017-11-06
KR20170003567A (ko) 2017-01-09
ES2649491T3 (es) 2018-01-12
LT3054950T (lt) 2017-11-27
RU2016148182A3 (el) 2018-06-13
EP3054950A1 (en) 2016-08-17
US20180111944A1 (en) 2018-04-26
TN2016000497A1 (en) 2018-04-04
PT3054950T (pt) 2017-11-29
US20170145015A1 (en) 2017-05-25
HRP20171650T1 (hr) 2017-12-15
KR102232198B1 (ko) 2021-03-26
CA2948596A1 (en) 2015-11-12
RS56590B1 (sr) 2018-02-28
AU2014393489B2 (en) 2020-01-02
JP2017514884A (ja) 2017-06-08
WO2015171004A1 (en) 2015-11-12
SI3054950T1 (sl) 2017-12-29
NZ726131A (en) 2018-12-21
MA39448A1 (fr) 2018-08-31
RU2695607C2 (ru) 2019-07-24
AU2014393489A1 (en) 2016-11-24
US10533012B2 (en) 2020-01-14
NO3054950T3 (el) 2017-12-30
PH12016502236A1 (en) 2017-02-06
MX2016014701A (es) 2017-05-23

Similar Documents

Publication Publication Date Title
CY1125205T1 (el) Φαρμακευτικες συνθεσεις δραστικων απο θεραπευτικη αποψη ενωσεων
MY187540A (en) Compounds active towards bromodomains
TW201613887A (en) Antiproliferative compounds and methods of use thereof
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
WO2015160975A3 (en) Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
MX2017002489A (es) Agentes terapeuticos humanos.
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
CY1121566T1 (el) Νευροπροστατευτικο και ενδειξη αυτου
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
PH12016502243A1 (en) Pharmaceutical compositions for treating infectious diseases
MX2015013755A (es) Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.
HK1243327A1 (zh) 包含螺旋藻和棕櫚酰基乙醇酰胺和/或其鹽或藥用上可接受衍生物的組合及其製劑，用於預防和/或治療過度活化的組織病症
HK1251476A1 (zh) 用於治療癌症的氨基硫羥酸酯化合物或其藥學上可接受的鹽
WO2016082807A3 (zh) 伊曲康唑的新用途
EA201790020A1 (ru) Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний
BR112016025244A2 (pt) uso de ácido 1,3-propanodissulfônico ou sais farmaceuticamente aceitáveis dos mesmos para o tratamento de sarcoidose.
SG10201903630UA (en) Iminosugars useful for the treatment of viral diseases
MX2017001512A (es) Compuestos activos hacia bromodominios.
TH167850B (th) (r)-เพอร์ลินโดล และเกลือที่ยอมรับได้ทางเภสัชกรรมของมันสำหรับการใช้ ในยารักษาโรค
TH1601006737A (th) (r)-เพอร์ลินโดล และเกลือที่ยอมรับได้ทางเภสัชกรรมของมันสำหรับการใช้ ในยารักษาโรค
EA201692164A1 (ru) Лекарственное средство для лечения пациентов с тиннитусом
IN2014MU00077A (el)